Compare ATEC & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | WVE |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2006 | 2015 |
| Metric | ATEC | WVE |
|---|---|---|
| Price | $8.28 | $5.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $22.00 | ★ $29.81 |
| AVG Volume (30 Days) | 2.3M | ★ 3.5M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.04 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $101,739,000.00 | $3,704,000.00 |
| Revenue This Year | $18.97 | N/A |
| Revenue Next Year | $16.70 | $85.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $6.82 | $5.02 |
| 52 Week High | $23.29 | $21.73 |
| Indicator | ATEC | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 39.51 |
| Support Level | $7.27 | $5.02 |
| Resistance Level | $8.42 | $7.65 |
| Average True Range (ATR) | 0.38 | 0.32 |
| MACD | 0.16 | 0.03 |
| Stochastic Oscillator | 90.58 | 37.34 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.